Medtronic Neurovascular, a pioneer and global leader in stroke care, is proud to announce the appointment of Dr. Adam S. Arthur as Chief Medical Officer, effective September 30, 2025. Dr. Arthur brings more than 20 years of experience as a practicing neurosurgeon, having previously served as Chair of Neurosurgery at the University of Tennessee Health Science Center. His leadership in clinical trials and commitment to innovation have driven improved outcomes for stroke patients and advanced the field of neurovascular care.
Arthur’s addition to Medtronic Neurovascular exemplifies the company’s founding principle: bringing clinical expertise to industry. For more than 75 years, Medtronic’s success has been built on the partnership between physicians and engineers – a collaboration that continues to accelerate advancements in patient care and shape the future of Neurosciences.
“It’s an exciting time to be a part of the Neurovascular team as we focus on creating future breakthroughs in stroke care,” said Linnea Burman, President, Medtronic Neurovascular. “I’m confident Dr. Arthur will play an important role in advancing our goal of helping more stroke patients access world-class neurovascular care.”
“I’m excited and honored to join the team at Medtronic Neurovascular as Chief Medical Officer,” said Arthur, chief medical officer, Medtronic Neurovascular. “My top priority is improving care for patients, and this role allows me to be closer to the innovations that will deliver better patient outcomes.”
In his new role, Arthur will guide clinical development strategy, strengthen relationships within the physician community, and further Medtronic’s commitment to continually improving patient outcomes. Arthur will continue to devote a portion of his time to patient care through his practice at Semmes Murphey and remain on the faculty at University of Tennessee’s Health Science Center’s College of Medicine.
